Anastasia Katsoula1,2, Paschalis Paschos1,2, Anna-Bettina Haidich3, Apostolos Tsapas2,4, Olga Giouleme1. 1. Second Propedeutic Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. 2. Clinical Research and Evidence-Based Medicine Unit, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. Department of Hygiene and Epidemiology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. 4. Harris Manchester College, University of Oxford, Oxford, United Kingdom.
Abstract
Importance: The potential role of the fecal immunochemical test (FIT) for screening patients at increased risk for colorectal cancer (CRC) has not yet been elucidated. Objective: To assess the diagnostic accuracy of FIT for CRC or advanced neoplasia (AN) in asymptomatic patients at above-average risk. Data Sources: MEDLINE, EMBASE, Cochrane Library, and gray literature sources through August 2016. Study Selection: Diagnostic studies evaluating the accuracy of FIT for CRC or AN in patients with a personal or familial history of CRC using colonoscopy as the reference standard. Data Extraction and Synthesis: Two authors (A.K. and P.P.) independently extracted data and evaluated study quality using the Quality Assessment of Diagnostic Accuracy Studies-2 tool, and evaluated the quality of the body of evidence by means of GRADE (Grading of Recommendations Assessment, Development, and Evaluation). Hierarchical models were used to synthesize available evidence. Main Outcomes and Measures: The primary outcome was the diagnostic performance of FIT for detecting CRC or AN. Results: We included 12 studies (6204 participants). Seven studies were deemed at high or unclear risk of bias. The average sensitivity of FIT for CRC was 93% (95% CI, 53%-99%), and the average specificity was 91% (95% CI, 89%-92%), yielding a positive likelihood ratio (LR+) of 10.30 (CI 7.7-13.9) and a negative likelihood ratio (LR-) of 0.08 (95% CI, 0.01-0.75) (GRADE: very low). The average sensitivity of FIT for AN was 48% (95% CI, 39%-57%); and the average specificity was 93% (95% CI, 91%-94%), yielding an LR+ of 6.55 (95% CI, 5.0-8.5) and an LR- of 0.57 (95% CI, 0.48-0.67) (GRADE: very low). Subgroup analyses indicated that FIT cutoff values between 15- and 25-μg/g feces provided the best combination of sensitivity and specificity for the diagnosis of CRC (93% and 94%, respectively). Quantitative and 1-sample FIT showed adequate test performance, but data on other FIT brands and multiple samples were insufficient. Conclusions and Relevance: The FIT has high overall diagnostic accuracy for CRC but moderate accuracy for AN in patients at above-average personal or familial risk. Heterogeneity and wide confidence intervals limit the trustworthiness of our findings.
Importance: The potential role of the fecal immunochemical test (FIT) for screening patients at increased risk for colorectal cancer (CRC) has not yet been elucidated. Objective: To assess the diagnostic accuracy of FIT for CRC or advanced neoplasia (AN) in asymptomatic patients at above-average risk. Data Sources: MEDLINE, EMBASE, Cochrane Library, and gray literature sources through August 2016. Study Selection: Diagnostic studies evaluating the accuracy of FIT for CRC or AN in patients with a personal or familial history of CRC using colonoscopy as the reference standard. Data Extraction and Synthesis: Two authors (A.K. and P.P.) independently extracted data and evaluated study quality using the Quality Assessment of Diagnostic Accuracy Studies-2 tool, and evaluated the quality of the body of evidence by means of GRADE (Grading of Recommendations Assessment, Development, and Evaluation). Hierarchical models were used to synthesize available evidence. Main Outcomes and Measures: The primary outcome was the diagnostic performance of FIT for detecting CRC or AN. Results: We included 12 studies (6204 participants). Seven studies were deemed at high or unclear risk of bias. The average sensitivity of FIT for CRC was 93% (95% CI, 53%-99%), and the average specificity was 91% (95% CI, 89%-92%), yielding a positive likelihood ratio (LR+) of 10.30 (CI 7.7-13.9) and a negative likelihood ratio (LR-) of 0.08 (95% CI, 0.01-0.75) (GRADE: very low). The average sensitivity of FIT for AN was 48% (95% CI, 39%-57%); and the average specificity was 93% (95% CI, 91%-94%), yielding an LR+ of 6.55 (95% CI, 5.0-8.5) and an LR- of 0.57 (95% CI, 0.48-0.67) (GRADE: very low). Subgroup analyses indicated that FIT cutoff values between 15- and 25-μg/g feces provided the best combination of sensitivity and specificity for the diagnosis of CRC (93% and 94%, respectively). Quantitative and 1-sample FIT showed adequate test performance, but data on other FIT brands and multiple samples were insufficient. Conclusions and Relevance: The FIT has high overall diagnostic accuracy for CRC but moderate accuracy for AN in patients at above-average personal or familial risk. Heterogeneity and wide confidence intervals limit the trustworthiness of our findings.
Authors: Jason A Dominitz; Glenn M Eisen; Todd H Baron; Jay L Goldstein; William K Hirota; Brian C Jacobson; John F Johanson; Jonathan A Leighton; J Shawn Mallery; Hareth M Raddawi; John J Vargo; J Patrick Waring; Robert D Fanelli; Jo Wheeler-Harbough; Douglas O Faigel Journal: Gastrointest Endosc Date: 2003-04 Impact factor: 9.427
Authors: Thomas R de Wijkerslooth; Margriet C de Haan; Esther M Stoop; Patrick M Bossuyt; Maarten Thomeer; Monique E van Leerdam; Marie-Louise Essink-Bot; Paul Fockens; Ernst J Kuipers; Jaap Stoker; Evelien Dekker Journal: Am J Gastroenterol Date: 2012-12 Impact factor: 10.864
Authors: Zohar Levi; Paul Rozen; Rachel Hazazi; Alex Vilkin; Amal Waked; Eran Maoz; Shlomo Birkenfeld; Moshe Leshno; Yaron Niv Journal: Ann Intern Med Date: 2007-02-20 Impact factor: 25.391
Authors: Enrique Quintero; Antoni Castells; Luis Bujanda; Joaquín Cubiella; Dolores Salas; Ángel Lanas; Montserrat Andreu; Fernando Carballo; Juan Diego Morillas; Cristina Hernández; Rodrigo Jover; Isabel Montalvo; Juan Arenas; Eva Laredo; Vicent Hernández; Felipe Iglesias; Estela Cid; Raquel Zubizarreta; Teresa Sala; Marta Ponce; Mercedes Andrés; Gloria Teruel; Antonio Peris; María-Pilar Roncales; Mónica Polo-Tomás; Xavier Bessa; Olga Ferrer-Armengou; Jaume Grau; Anna Serradesanferm; Akiko Ono; José Cruzado; Francisco Pérez-Riquelme; Inmaculada Alonso-Abreu; Mariola de la Vega-Prieto; Juana Maria Reyes-Melian; Guillermo Cacho; José Díaz-Tasende; Alberto Herreros-de-Tejada; Carmen Poves; Cecilio Santander; Andrés González-Navarro Journal: N Engl J Med Date: 2012-02-23 Impact factor: 91.245
Authors: O Otero-Estévez; L De Chiara; F J Rodríguez-Berrocal; M Páez de la Cadena; J Cubiella; I Castro; C Gonzalez-Mao; V Hernandez; V S Martínez-Zorzano Journal: Br J Cancer Date: 2014-12-02 Impact factor: 7.640
Authors: Chi Thi-Du Tran; Mai Vu-Tuyet Nguyen; Mo Thi Tran; Thuy Thi-Van Tuong; Quang Hong Tran; Linh Cu Le; Huong Thi-Thu Pham; Nam Chi Bui; Hien Huy Vu; Tu Thi-Cam Nguyen; Phuong Que Ta; Hien Thi-Thu Ha; Dung Tuan Trinh; Hanh Thi-My Bui; Dien Quang Trinh; Khanh Van Nguyen; Song Huu Le; Khien Van Vu; Thuan Van Tran; Huong Thi-Thanh Tran; Martha J Shrubsole; Fei Ye; Qiuyin Cai; Wei Zheng; Paolo Boffetta; Xiao-Ou Shu; Hung N Luu Journal: Jpn J Clin Oncol Date: 2022-07-08 Impact factor: 2.925
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059
Authors: Samir Gupta; Gloria D Coronado; Keith Argenbright; Alison T Brenner; Sheila F Castañeda; Jason A Dominitz; Beverly Green; Rachel B Issaka; Theodore R Levin; Daniel S Reuland; Lisa C Richardson; Douglas J Robertson; Amit G Singal; Michael Pignone Journal: CA Cancer J Clin Date: 2020-06-25 Impact factor: 286.130
Authors: Charles R Rogers; Tiana N Rogers; Phung Matthews; Nathan Le Duc; Susan Zickmund; Wizdom Powell; Roland J Thorpe; Alicia McKoy; France A Davis; Kola Okuyemi; Electra D Paskett; Derek M Griffith Journal: Ethn Health Date: 2020-11-29 Impact factor: 2.732